名稱(chēng) | PD1/41BB Dual Effector Reporter Cell |
型號(hào) | CBP74172 |
報(bào)價(jià) | |
特點(diǎn) | PD1/41BB Dual Effector Reporter Cell |
產(chǎn)品搜索
產(chǎn)品分類(lèi)
相關(guān)文章
- 中國(guó)細(xì)胞資源庫(kù),南京科佰生物
- CD161抗體藥物篩選模型 簡(jiǎn)介
- Cell Rep:發(fā)現(xiàn)治療乳腺癌轉(zhuǎn)移的重要新靶標(biāo)!
- 非小細(xì)胞肺癌免疫治療 先放療更有效
- 腫瘤細(xì)胞的生長(zhǎng)受哪些因素的作用呢?
- CD74-ROS1的藥靶模型+DNARNA標(biāo)準(zhǔn)品+ddPCR試劑盒
- 神舟十一號(hào)成功發(fā)射!哪些生物實(shí)驗(yàn)跟著上天了?
- 【靶點(diǎn)模型+診斷質(zhì)控】BCR-ABL1的藥物開(kāi)發(fā)和診斷
- 你知道ATCC細(xì)胞如何解凍嗎?
- Canine IL-31細(xì)胞篩選模型
聯(lián)系我們
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > 腫瘤免疫細(xì)胞株 > CBP74172PD1/41BB Dual Effector Reporter Cell
- 詳細(xì)內(nèi)容
CBP74172 | |
I. Background | |
The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T-cells, to its ligands, PD-L1 and PD-L2, negatively regulates immune responses. The PD-1 ligands are found on most cancers, and PD-1:PD-L1/2 interaction inhibits T cell activity and allows cancer cells to escape immune surveillance. diabetes. Human CD137 (4-1BB; TNFRS9) is an inducible costimulatory molecule that activates T cells. CD137-CD137L mediated signaling has been shown to be important for proliferation, effector functions and survival of T cells. CD137 is also expressed in NK and NKT cells. Antibodies targeting CD137 activation in immune cells have demonstrated potent anti-tumor effects in cancer patients. | |
II. Introduction | |
Expressed gene: | PD1、41BB |
Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Freeze Medium: | 90% FBS+10% DMSO |
Culture Medium: | RPMI-1640+10%FBS+1ug/ml puromycin+800ug/ml hygromycin+10ug/ml blasticidin |
Mycoplasma Testing: | Negative |
Storage: | Liquid nitrogen |
Application(s): | Functional(Report Gene) Assay |
III. Representative Data | |
Figure 1. Dose Response of Blocking Antibodies in PD-1/41BB Dual Effector Reporter Cells (C64) With PD-L1 aAPC Cells. | |